|
Regulatory
Matters
|
|
•
|
Botulinum
toxin type A |
|
•
|
Fentanyl
transdermal patches |
|
•
|
Magnesium
oxide |
|
•
|
Nitrous
oxide |
|
•
|
Oral
sodium phosphate products |
|
•
|
Rituximab
and efalizumab |
|
•
|
Tacrolimus |
|
•
|
Toremifene |
| Safety
of Medicines |
|
•
|
Bevacizumab |
|
•
|
Herbal
cold and flu products |
|
•
|
Icodextrin,
intravenous immunoglobulins, galactose and d-xylose |
|
•
|
Local
anaesthetics with infusion devices |
|
•
|
Modafinil |
|
•
|
Natural
health products |
|
•
|
Temsirolimus |
|
•
|
Tinzaparin
sodium injection |
|
•
|
Topical
anaesthetics |
|
•
|
Varenicline |
|
•
|
Weight
loss pills |
|
Feature
|
|
•
|
Use
of the ATC/DDD methodology: an international survey |
